Labroots

Mass Photometry sheds light on the binding mechanism of the bispecific tetravalent anti-VEGF-PD-1 antibody Ivonescimab

Ivonescimab is a next-generation bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), two key molecules in the tumour ...

Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026

New in vivo data demonstrate exceptional selectivity, localization and potency of MDNA113 in the tumor and tumor microenvironment while enhancing ...
EurekAlert!

Blocking the PD-1 signal transduction by occupying the phosphorylated ITSM recognition site of SHP-2

In recent years, immune checkpoint therapy headed by programmed death receptor 1 (PD-1) and programmed death receptor-ligand 1 (PD-L1) has been proven to be safe and effective. However, clinical ...
ascopubs.org

Long-Term Follow-Up of Real-World Adjuvant Anti–PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma

NOTE. Extended FU data were received for 490 patients. Eighty-three patients had already died at the time of the 2-year analysis. Nine patients in the PD-1–treated arm and seven patients in the TT arm ...
The American Journal of Managed Care

Will Subcutaneous PD-1/PD-L1 Inhibitors Be a Game Changer?

With Bristol Myers Squibb (BMS) now rolling out the SC version of rival nivolumab (Opdivo Qvantig), the shift from 30-minute intravenous (IV) infusion to 5-minute SC injection could be one of the most ...